Tenofovir/emtricitabine

Also Known As: Tenofovir/emtricitabine, Truvada

Tenofovir/emtricitabine, trademark Truvada by Gilead Sciences, is a fixed-dose combination of twoantiretroviral drugs used for the treatment of HIV. It consists of 300 milligrams of tenofovir and 200 milligrams of emtricitabine.

The drug has been examined for use as a pre-exposure prophylaxis against HIV infection. A Cochrane review found that both tenofovir alone, as well as the tenofovir/emtricitabine combination, significantly decreased the risk of contracting HIV.[1] The Food and Drug Administration approved it for prophylactic use on July 16, 2012.[2] It is estimated that daily intake of Truvada achieves a 99% of risk reduction of contracting HIV in high risk individuals.[3]

In certain studies, the drug has demonstrated rare side effects including: transient nausea, dizziness, loss of appetite and loose stools.[4]

Print this Page

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

Effectiveness:
  • 0 = No improvement or Worse
  • 1 = Slight improvement
  • 2 = Moderate Improvement
  • 3 = Significant Improvement
  • 4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Embed

Complete a survey on Tenofovir/emtricitabine to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.